The Humanized Mouse Platform of Alfa Cytology Facilitates Preclinical Studies of Immunotherapy Drugs

NEW YORK, NY May 30, 2026 /24-7PressRelease/ — The Hu-Immune™ humanized mouse platform of Alfa Cytology provides experimental conditions closer to the human body, helping research teams to efficiently evaluate drug efficacy and immune mechanisms and accelerate preclinical translation. Immunotherapy is developing rapidly in the treatment of tumors and autoimmune diseases. However, traditional mouse models often cannot accurately predict the human immune response. This results in high uncertainty and R&D costs for drug candidates in the early validation phase.

The development of immunotherapy drugs involves multiple steps, such as candidate drug screening, efficacy verification, immune mechanism analysis, and safety evaluation. With the huPBMC and huHSC humanized mouse model services, Alfa Cytology has built a systematic research pipeline that provides continuous support from candidate discovery to in vivo validation, allowing research teams to more efficiently assess drug potential.

On this platform, researchers can analyze the tumor targeting and immunomodulatory effects of drugs under conditions that mimic the human immune environment. Alfa Cytology offers a variety of tumor models, including orthotopic, metastatic, and drug-resistant tumor models, for tumor growth monitoring, immune microenvironment analysis and in vivo drug distribution studies. These experiments provide reliable data for optimizing therapeutic strategies while improving the efficiency of preclinical translation.

Meanwhile, the humanized mouse platform of Alfa Cytology emphasizes the reproducibility and reliability of experimental data. Using standardized operating procedures and validation across multiple models, the research team obtained consistent in vivo data. These data provide a scientific basis for drug optimization, dose design, and combination therapy strategies. This not only improves the accuracy of preclinical decision-making but also helps shorten the time from candidate screening to preclinical validation.

In addition, in vivo immunotherapy testing services also support the research of combination therapy strategies, covering candidate drug screening, functional verification, and in vivo evaluation. Research teams have been able to complete critical validation phases in a unified pipeline, ensure experimental continuity, and accelerate the development of innovative immunotherapeutic options.

“Preclinical validation data is central to the evaluation of the efficacy and feasibility of immunotherapy drugs,” said a spokesperson for Alfa Cytology. “The huPBMC and huHSC humanized mouse model services and in vivo immunotherapy testing services will allow the research team to conduct experiments in more human-relevant conditions and provide a solid foundation for preclinical translation.”

About Alfa Cytology
Alfa Cytology focuses on the preclinical research support of immunotherapy drug development, providing systematic research solutions to global biotechnology companies, pharmaceutical institutions, and scientific research teams. The company integrates advanced experimental technology, humanized mouse model resources, and a professional research platform to provide experimental systems and technical support for the preclinical translational research of various immunotherapy drugs. It also helps scientific research achievements advance from the laboratory to preclinical development.

—
For the original version of this press release, please visit 24-7PressRelease.com here